美股详情

本页面由Tiger Fintech (Singapore) Pte. Ltd.提供服务

Innovent Biologics Inc.

51.09

0.0000

成交量：- -

成交额：- -

市值：207.94亿

市盈率：-6,215.33

高：51.09

开：51.09

低：51.09

收：51.09

52周最高：52.00

52周最低：19.15

股本：4.07亿

流通股本：4.07亿

量比：0.54

换手率：- -

股息：- -

股息率：- -

每股收益(TTM):-0.0082

每股收益(LYR):-0.0080

净资产收益率：8.43%

总资产收益率：2.65%

市净率：10.28

市盈率(LYR):-6,413.51

数据加载中...

总览公司新闻公告

信达生物合作伙伴 Ollin 公布眼科双抗IBI324（抗VEGF/ANG-2双特异性抗体）临床进展

信达生物将在第34届欧洲皮肤病学会（EADV）2025年会公布综合管线免疫领域多项研究数据

信达生物宣布IBI128（替古索司他片，XOI）痛风临床II期研究结果于亚太风湿病协会联盟大会（APLAR）公布

信达生物2025年度中期业绩亮点

信达生物全球首创抗VEGF-补体双靶融合蛋白

荣获七项ASCO口头报告：信达生物IBI363（PD-1/IL-2α-bias）领衔多款管线亮相美国临床肿瘤学会2025年大会

信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期黑色素瘤

信达生物将在美国癌症研究协会（AACR）2025年会公布多项临床前数据

信达生物2024年度业绩亮点

信达生物IBI354 (创新型HER2 ADC) 治疗铂耐药卵巢癌的III期临床研究完成首例受试者给药

{"basename":"/hans","ssrTDKData":{"titleTemplate":"%s - 老虎证券","title":"老虎证券全球投资理财平台| 一站式投资美股新股港股A股","description":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","keywords":"老虎证券,老虎证券开户,老虎券商,老虎证券官网,老虎证券app,tigertrade老虎证券,股票,炒股,新加坡股票交易平台,投资,投资理财","social":{"ogDescription":"老虎证券助您一站式投资美股，新股，港股，A股等全球金融理财产品。新加坡华人最信赖的在线投资平台，现在加入即享低费用，24/5 无时差炒美股投资理财！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hans/stock/IVBIY/news"},"companyName":"老虎证券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"IVBIY","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVBIY\",,,,,undefined,":{"symbol":"IVBIY","market":"US","secType":"STK","nameCN":"Innovent Biologics Inc.","latestPrice":51.09,"timestamp":1760731200000,"preClose":51.09,"halted":0,"volume":0,"delay":15,"floatShares":407000000,"shares":407000000,"eps":-0.00822,"marketStatus":"休市中","change":0,"latestTime":"10-17 16:00:00 EDT 延时","open":51.09,"high":51.09,"low":51.09,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.00822,"tradingStatus":0,"nextMarketStatus":{"tag":"盘前交易","tradingStatus":1,"beginTime":1760947200000},"marketStatusCode":7,"adr":0,"adrRate":4,"exchange":"PINK LIMITED","adjPreClose":51.09,"volumeRatio":0.5434781131852954},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IVBIY\",,,,,undefined,":{"symbol":"IVBIY","floatShares":407000000,"roa":"2.65%","roe":"8.43%","lyrEps":-0.007966,"volumeRatio":0.5434781131852954,"shares":407000000,"dividePrice":0,"high":51.09,"amplitude":0,"preClose":51.09,"low":51.09,"week52Low":19.15,"pbRate":"10.28","psRate":"12.97","week52High":52,"institutionHeld":0,"latestPrice":51.09,"eps":-0.00822,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.00822,"open":51.09,"prevYearClose":19.15,"prevWeekClose":51.09,"prevMonthClose":51.09,"prevQuarterClose":51.09,"fiveDayClose":51.09,"twentyDayClose":48,"sixtyDayClose":39.5},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IVBIY\",params:#limit:5,,,undefined,":[{"market":"US","date":"2024-08-28","symbol":"IVBIY","fiscalQuarterEnding":null,"expectedEps":null,"name":null,"time":"盘前","type":"earning","dateTimestamp":1724817600000,"reportTimeType":"pre","actualEps":null}],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IVBIY\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"IVBIY\",market:\"US\",delay:false,,,undefined,":{"strongBuy":0.4333,"buy":0.4667,"hold":0.1,"sell":0,"strongSell":0,"meanLabel":"BUY","meanPercent":0.4667,"analysts":30,"updateTime":1757044800000},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IVBIY\",pageSize:20,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2568440013","title":"信达生物合作伙伴 Ollin 公布眼科双抗IBI324（抗VEGF/ANG-2双特异性抗体）临床进展","url":"https://stock-news.laohu8.com/highlight/detail?id=2568440013","media":"美通社","labels":["corporation"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2568440013?lang=zh_cn&edition=fundamental","pubTime":"2025-09-18 12:00","pubTimestamp":1758168000,"startTime":"0","endTime":"0","summary":"预计该研究的初步结果将于 2026 年第一季度公布。作为新一代 VEGF/Ang2 双特异性抗体，OLN324有望在解剖学治疗结局和疗效持久性方面优于法瑞西单抗等现有标准治疗药物。信达生物将继续与 Ollin 保持协同，加快 OLN324 的研发进程，推动这一急需的治疗方案在全球范围内上市。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4775625_ZH75625_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"corporation","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2328871848.SGD","BK4139","LU0455707207.USD","IVBIY","LU2097828474.EUR","01801","LU2488822045.USD","LU2097828557.USD","LU2097828714.EUR","BK1161","BK1583","BK1589","LU0502904849.HKD","LU1969619763.USD","LU2097828631.EUR","LU2242644610.SGD","LU2097828805.USD"],"gpt_icon":0},{"id":"2567770701","title":"信达生物将在第34届欧洲皮肤病学会（EADV）2025年会公布综合管线免疫领域多项研究数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2567770701","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2567770701?lang=zh_cn&edition=fundamental","pubTime":"2025-09-16 09:00","pubTimestamp":1757984400,"startTime":"0","endTime":"0","summary":"2025年9月16日美国旧金山和中国苏州 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在2025年欧洲皮肤病学会年会上公布综合管线的多项最新研究数据，包括匹康奇拜单抗的临床II期及III期研究事后分析，IBI3013和IAR129的临床前研究。截至目前，信达生物患者援助项目已惠及17余万普通患者，药物捐赠总价值34亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4773327_ZH73327_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2242644610.SGD","BK1589","LU2328871848.SGD","BK1583","LU2488822045.USD","CVM","LU1969619763.USD","BK1161","01801","LU0455707207.USD","BK4139","IVBIY","LU2097828557.USD","LU2097828631.EUR","LU2097828805.USD","LU2097828474.EUR","LU2097828714.EUR","LU0502904849.HKD"],"gpt_icon":0},{"id":"2566300156","title":"信达生物宣布IBI128（替古索司他片，XOI）痛风临床II期研究结果于亚太风湿病协会联盟大会（APLAR）公布","url":"https://stock-news.laohu8.com/highlight/detail?id=2566300156","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2566300156?lang=zh_cn&edition=fundamental","pubTime":"2025-09-08 08:30","pubTimestamp":1757291400,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年9月8日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司宣布：黄嘌呤氧化酶抑制剂替古索司他片在中国痛风患者中的II期临床研究的主要结果在2025年亚太风湿病协会联盟大会发表。基于该积极结果，信达生物计划于2025年下半年启动替古索司他片中国注册临床III期研究。替古索司他片安全性良好。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4766503_ZH66503_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2328871848.SGD","LU2097828805.USD","LU1969619763.USD","BK1583","IVBIY","LU0455707207.USD","01801","BK4139","LU2097828474.EUR","LU2097828557.USD","LU2097828714.EUR","LU2242644610.SGD","LU2488822045.USD","LU0502904849.HKD","BK1589","LU2097828631.EUR","BK1161"],"gpt_icon":0},{"id":"2562775216","title":"信达生物2025年度中期业绩亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=2562775216","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562775216?lang=zh_cn&edition=fundamental","pubTime":"2025-08-27 17:46","pubTimestamp":1756287960,"startTime":"0","endTime":"0","summary":"信达生物制药集团创始人、董事会主席、首席执行官俞德超博士表示：\"2025年上半年我们交出了一份令人振奋的成绩单，双轮驱动与全球创新战略全面提速。在创新端，多款具备全球化潜力的核心管线取得关键性概念验证数据，并逐渐迈入全球注册临床开发，标志着信达生物创新力的厚积薄发，也为全球化拓展夯实了根基。我们坚信，清晰的战略方向与卓越的执行能力将持续驱动信达生物不断突破边界。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4760123_ZH60123_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2488822045.USD","LU2097828631.EUR","BK1161","IVBIY","LU1969619763.USD","BK4139","01801","LU2097828714.EUR","LU2097828557.USD","LU2097828805.USD","LU2328871848.SGD","LU2097828474.EUR","BK1589","BK1583"],"gpt_icon":0},{"id":"2533596248","title":"信达生物全球首创抗VEGF-补体双靶融合蛋白","url":"https://stock-news.laohu8.com/highlight/detail?id=2533596248","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2533596248?lang=zh_cn&edition=fundamental","pubTime":"2025-05-06 08:00","pubTimestamp":1746489600,"startTime":"0","endTime":"0","summary":"值得关注的是，全球首个创新型双靶点分子IBI302II期数据显示其高剂量组达到主要研究终点，一年期最佳矫正视力较基线提升10个字母左右，超过80%的受试者能够维持长达12周及以上的给药间隔。\" 关于依莫芙普 依莫芙普是信达生物拥有全球知识产权的一种双特异性重组全人源融合蛋白，研发代号：IBI302。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4679597_ZH79597_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","LU2328871848.SGD","LU1969619763.USD","BK1589","BK1161","BK1583","LU2488822045.USD","BK4139","01801"],"gpt_icon":0},{"id":"2529693739","title":"荣获七项ASCO口头报告：信达生物IBI363（PD-1/IL-2α-bias）领衔多款管线亮相美国临床肿瘤学会2025年大会","url":"https://stock-news.laohu8.com/highlight/detail?id=2529693739","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2529693739?lang=zh_cn&edition=fundamental","pubTime":"2025-04-24 07:00","pubTimestamp":1745449200,"startTime":"0","endTime":"0","summary":"本届 ASCO 年会将于当地时间2025年5月30日-6月3日在美国芝加哥举办。信达生物制药集团高级副总裁周辉博士表示：\"很高兴在本次ASCO大会上，IBI363开发的第一批三大适应症黑色素瘤、肠癌、非小细胞肺癌的临床研究均被接收为口头报告，代表了下一代PD-1双抗肿瘤免疫疗法引起了全球的广泛关注。同时IBI343胰腺癌研究继去年12月ESMO Asia口头报告之后，再次以口头报告登上ASCO舞台。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4671176_ZH71176_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU1169590202.USD","BK4023","BK1589","LU2488822045.USD","BK1161","LU1969619763.USD","IVBIY","PD","01801","LU1169589451.USD","LU2328871848.SGD","BK1583","BK4139"],"gpt_icon":1},{"id":"2523895478","title":"信达生物IBI363（PD-1/IL-2α-bias双特异性抗体融合蛋白）获国家药品监督管理局纳入突破性治疗药物品种，治疗晚期黑色素瘤","url":"https://stock-news.laohu8.com/highlight/detail?id=2523895478","media":"美通社","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2523895478?lang=zh_cn&edition=fundamental","pubTime":"2025-03-31 09:10","pubTimestamp":1743383400,"startTime":"0","endTime":"0","summary":"IBI363已开出首个关键注册临床研究，用于治疗未经免疫治疗的粘膜型和肢端型黑色素瘤。IBI363已获美国FDA两项快速通道资格认定，分别用于治疗晚期鳞状非小细胞肺癌和黑色素瘤。IBI363也获得中国NMPA纳入突破性治疗药物品种，治疗晚期黑色素瘤。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4653208_ZH53208_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["LU2328871848.SGD","LU1969619763.USD","01801","BK4023","BK4139","IVBIY","PD","LU2488822045.USD","LU1169590202.USD","BK1161","BK1583","BK1589","LU1169589451.USD"],"gpt_icon":0},{"id":"2522296398","title":"信达生物将在美国癌症研究协会（AACR）2025年会公布多项临床前数据","url":"https://stock-news.laohu8.com/highlight/detail?id=2522296398","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522296398?lang=zh_cn&edition=fundamental","pubTime":"2025-03-27 09:17","pubTimestamp":1743038220,"startTime":"0","endTime":"0","summary":"美国旧金山和中国苏州2025年3月27日 /美通社/ -- 信达生物制药集团，一家致力于研发、生产和销售肿瘤、自身免疫、代谢及心血管、眼科等重大疾病领域创新药物的生物制药公司，今日宣布，将在 2025 年美国癌症研究协会年会上公布多项最新临床前数据，包括公司旗下一系列双抗、多抗及抗体偶联药物肿瘤管线。截至目前，信达生物患者援助项目已惠及20余万普通患者，药物捐赠总价值36亿元人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4651166_ZH51166_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK1583","01801","BK4231","BK4080","LU0266512127.USD","BK1161","BK1589","IVBIY","CRC","LU0456854461.SGD","LU2488822045.USD","BK4213","LU2328871848.SGD","LU1969619763.USD","BK4139","ADC"],"gpt_icon":0},{"id":"2522380074","title":"信达生物2024年度业绩亮点","url":"https://stock-news.laohu8.com/highlight/detail?id=2522380074","media":"美通社","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2522380074?lang=zh_cn&edition=fundamental","pubTime":"2025-03-26 18:30","pubTimestamp":1742985000,"startTime":"0","endTime":"0","summary":"信达生物制药集团创始人、董事长兼CEO俞德超博士表示：\"作为中国生物制药行业可持续发展的先行者，2024年我们取得了历史性突破——公司率先实现了Non-IFRS净利润和EBITDA转正。再度荣登《2024中国最具吸引力雇主榜单》。信达生物共有7000名员工，累计为应届生提供1800多份就业岗位。截至目前，信达生物制药集团累计纳各类税费等50多亿人民币。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4650318_ZH50318_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["IVBIY","01801","LU2488822045.USD","BK4139","LU2328871848.SGD","BK1589","BK1161","BK1583","LU1969619763.USD"],"gpt_icon":0},{"id":"2521771068","title":"信达生物IBI354 (创新型HER2 ADC) 治疗铂耐药卵巢癌的III期临床研究完成首例受试者给药","url":"https://stock-news.laohu8.com/highlight/detail?id=2521771068","media":"美通社","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2521771068?lang=zh_cn&edition=fundamental","pubTime":"2025-03-24 08:00","pubTimestamp":1742774400,"startTime":"0","endTime":"0","summary":"同时，IBI354治疗展现出明显优于其它ADC的优秀临床安全性和治疗耐受性。\" 信达生物制药集团高级副总裁周辉博士表示：\"很高兴IBI354在HER2表达的铂耐药卵巢癌的临床III期研究完成首例受试者首次给药，也十分期待IBI354获得积极结果，为HER2表达的铂耐药卵巢癌患者提供更理想的治疗选择。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://wwwold.prnasia.com/story/archive/4647606_ZH47606_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["01801","BK1161","ADC","BK4080","BK4231","BK4134","LU2328871848.SGD","BK1589","III","BK4139","IVBIY","LU1969619763.USD","LU2488822045.USD","BK1583"],"gpt_icon":0}],"pageSize":20,"totalPage":1,"pageCount":1,"totalSize":10,"code":"91000000","status":"200"}]}}